The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.

This statistic illustrates the distribution of blood groups in the French population, according to the ABO system. It states that less than **** percent of French people have the AB blood group.

More than twelve blood group systems have been described in dogs, but little is known about their distribution frequencies within breed populations. Here, we report on an extensive typing survey carried out using available reagents and either established or new clinical kits in purebred dogs from Germany. Leftover anticoagulated blood samples were examined using an immunochromatographic strip method for DEA 1, a gel column technique for Dal and Kai 1/2, and new card agglutination tests for DEA 4 and DEA 5 (which were partially compared with the gel column technique). Monoclonal antibodies were used for DEA 1 and Kai 1/2 typing, and polyclonal antibodies were used for all other types. Among the 206 dogs, 59.2% were DEA 1+, 100% DEA 4+, 9% (Card)/11% (Gel) DEA 5+, 89.3% Dal+, 96.6% Kai 1+, and 2.9% Kai 2+. None of the dogs were Kai 1+/2+, and only one was Kai 1–/2–. Dal– dogs were found in several breeds. Erythrocytes from most DEA 1+ dogs bound strongly on the strips. The agglutination reactions for DEA 5 on the new card tests were generally less than those on the gel column. The blood group pattern DEA 4+, DEA 5–, Dal+, Kai 1+/2– and either DEA 1+ or DEA 1– was found among 80% of the dogs. In this first extensive blood typing survey of purebred dogs from Europe, the proportions of positive and negative blood types were similar to those found in the United States and, for DEA 1, were also similar to those from other European countries, with considerable breed variation in blood types. The newer typing techniques seem to work well and will likely be useful for detecting and preventing specific blood type incompatibilities in the clinic.

This industry includes facilities that primarily collect (through donation), test, process and store blood for later use. The testing includes compatibility testing for transfusion and may include blood donation processing. The industry does not include facilities that primarily provide diagnostic tests.

12 Global import shipment records of Blood Group with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.

Analysis of the US blood-grouping reagents market showing a slight decline in 2024 but forecasting long-term growth to 4.6K tons and $335M by 2035, with insights on production, trade, and key suppliers.

7 Active Global Blood Group buyers list and Global Blood Group importers directory compiled from actual Global import shipments of Blood Group.

Statistics illustrates the import volume of Reagents; diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, whether or not put up in the form of kits; for blood grouping in El Salvador from 2007 to 2024 by trade partner.

Statistics illustrates the import volume of Blood-Grouping Reagents in Iceland from 2007 to 2024 by trade partner.

United States Imports: cif: Blood-Grouping Reagents data was reported at 3.860 USD mn in Dec 2021. This records a decrease from the previous number of 4.762 USD mn for Nov 2021. United States Imports: cif: Blood-Grouping Reagents data is updated monthly, averaging 1.862 USD mn from Jan 2002 (Median) to Dec 2021, with 240 observations. The data reached an all-time high of 8.397 USD mn in Jun 2017 and a record low of 0.077 USD mn in Feb 2006. United States Imports: cif: Blood-Grouping Reagents data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.JA132: Imports: by Commodity: 6 Digit HS Code: HS 30 to 48.

Automated Blood Grouping Analyzer Market Outlook

According to our latest research, the Global Automated Blood Grouping Analyzer market size was valued at $1.2 billion in 2024 and is projected to reach $2.5 billion by 2033, expanding at a robust CAGR of 8.4% during the forecast period of 2025–2033. The primary factor fueling this remarkable growth is the increasing global demand for safe and efficient blood transfusion services, which in turn drives the adoption of automated blood grouping analyzers across healthcare settings. The rising prevalence of chronic diseases, growing surgical procedures, and heightened awareness regarding blood safety standards are further accelerating the market’s expansion. Additionally, advancements in automation technology are enabling laboratories and blood banks to achieve higher accuracy, faster turnaround times, and reduced human error, making automated blood grouping analyzers an essential component in modern diagnostic and transfusion medicine.

Regional Outlook

North America currently holds the largest share of the Automated Blood Grouping Analyzer market, accounting for approximately 38% of the global market value in 2024. This dominance is attributed to the region's mature healthcare infrastructure, early adoption of advanced diagnostic technologies, and stringent regulatory policies that ensure high standards of blood safety. The presence of leading market players, robust R&D investments, and a high volume of blood transfusions further reinforce North America’s leadership position. The United States, in particular, remains the primary driver with extensive hospital networks, well-established blood banks, and continuous government initiatives to modernize healthcare services, propelling the uptake of automated blood grouping analyzers.

Asia Pacific emerges as the fastest-growing region in the Automated Blood Grouping Analyzer market, projected to register a remarkable CAGR of 10.2% from 2025 to 2033. This accelerated growth is driven by increasing healthcare expenditures, rapid expansion of hospital and diagnostic laboratory networks, and rising awareness about the importance of accurate blood typing in emerging economies such as China and India. Government initiatives to improve blood safety, coupled with public-private partnerships and investments in healthcare infrastructure, are creating significant opportunities for both local and international market players. Additionally, the region’s large population base and growing prevalence of conditions requiring transfusion support are further catalyzing demand for automated solutions.

Emerging economies in Latin America and the Middle East & Africa present a mixed outlook for the Automated Blood Grouping Analyzer market. While there is growing interest in upgrading blood transfusion services, these regions face challenges such as limited healthcare budgets, inadequate laboratory infrastructure, and slower regulatory harmonization. Nonetheless, targeted government policies, international donor support, and localized training programs are gradually improving adoption rates. There is a notable shift towards semi-automated analyzers in resource-constrained settings, where cost-effectiveness and ease of use are prioritized. As these regions continue to address infrastructure gaps and enhance healthcare delivery, moderate but steady market growth is anticipated.

Report Scope

Statistics illustrates the import volume of Reagents; diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, whether or not put up in the form of kits; for blood grouping in Guatemala from 2007 to 2024 by trade partner.

In 2023, there were an estimated ****** blood transfusion-associated adverse reactions in the United States that required any diagnostic or therapeutic intervention. This graph shows the estimated number of blood transfusion-associated adverse reactions in the United States in 2021 and 2023, by type.

Global Blood Bank Management Software Market was valued at USD 1.2 Billion in 2024 and is projected to reach USD 2.4 Billion by 2032, growing at a CAGR of 9.0% from 2025 to 2032.Key Market Drivers: Increasing Demand for Blood Transfusions and Donations: The blood bank management software market is being driven by an increase in surgical procedures, trauma cases, and chronic disease therapy that require blood transfusions. According to the World Health Organization (WHO), around 118.5 million blood donations are collected worldwide each year, with demand increasing by 6-8% annually. According to the American Red Cross, someone in the United States needs blood every two seconds, resulting in a daily requirement of around 29,000 units of red blood cells, underlining the crucial need for effective blood inventory systems.Technological Developments in Healthcare Informatics: The adoption of sophisticated technologies such as cloud computing, artificial intelligence, and blockchain in blood bank operations is driving market expansion. According to the US Department of Health and Human Services' Office of the National Coordinator for Health Information Technology, 94% of hospitals will have implemented at least basic electronic health record systems by 2023, with blood bank management becoming an increasingly important component. The European Commission's Digital Health Initiative discovered that healthcare facilities that used integrated blood bank software systems reduced transfusion-related mistakes by 61% between 2020 and 2023.

7 Active Global Blood Group suppliers, manufacturers list and Global Blood Group exporters directory compiled from actual Global export shipments of Blood Group.

Statistics illustrates consumption, production, prices, and trade of Reagents; diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, whether or not put up in the form of kits; for blood grouping in United States Virgin Islands from 2007 to 2024.

Transfusion Diagnostics Market Outlook

According to our latest research, the transfusion diagnostics market size reached USD 4.9 billion globally in 2024, supported by sustained demand for advanced blood screening and compatibility testing solutions. The market is experiencing a robust compound annual growth rate (CAGR) of 6.2% and is forecasted to achieve a value of USD 8.4 billion by 2033. This growth is primarily attributed to the rising global prevalence of chronic diseases, increasing surgical procedures, and the continual need for safe blood transfusion practices worldwide.

The expanding burden of chronic and infectious diseases, such as cancer, hemophilia, and HIV, is one of the most significant growth drivers for the transfusion diagnostics market. With the global population aging and the incidence of conditions requiring blood transfusions on the rise, healthcare systems are prioritizing the safety and efficacy of transfusion practices. This has led to increased investments in the development and adoption of advanced diagnostic technologies that enable more accurate blood typing, antibody screening, and disease detection. Additionally, the demand for high-throughput and automated solutions is rising, as hospitals and blood banks strive to process larger sample volumes with greater precision and reduced turnaround times. The growing awareness about the risks associated with transfusion-transmitted infections and the implementation of stringent regulatory guidelines are further fueling the adoption of sophisticated transfusion diagnostic products.

Another critical factor propelling market expansion is the rapid technological advancements in molecular diagnostics and immunoassay techniques. Innovations such as polymerase chain reaction (PCR)-based testing, next-generation sequencing, and multiplex immunoassays are enhancing the sensitivity and specificity of transfusion diagnostics. These technologies facilitate the early detection of infectious agents and rare blood group antigens, thereby improving patient outcomes and minimizing the risk of adverse transfusion reactions. The integration of digital health solutions and laboratory automation is also streamlining workflow efficiencies, reducing human error, and enabling real-time data sharing across healthcare networks. As healthcare providers increasingly embrace digital transformation, the role of software and data analytics in transfusion diagnostics is expanding, supporting more informed clinical decision-making.

The market’s growth is further supported by favorable government initiatives and public-private partnerships aimed at strengthening blood safety infrastructure, particularly in emerging economies. National screening programs, investments in healthcare infrastructure, and efforts to expand voluntary blood donation are creating new opportunities for market participants. However, challenges such as the high cost of advanced diagnostic instruments, limited access to skilled laboratory professionals in low-resource settings, and the need for continuous training and quality assurance remain obstacles to widespread adoption. Nonetheless, the overall outlook for the transfusion diagnostics market is positive, with ongoing innovations and collaborative efforts expected to address these challenges and drive sustained growth through 2033.

Regionally, North America continues to dominate the transfusion diagnostics market, accounting for the largest share in 2024, followed by Europe and the Asia Pacific. The United States, in particular, benefits from a well-established healthcare system, high awareness of blood safety, and significant investments in research and development. Europe’s growth is driven by stringent regulatory standards and a strong focus on transfusion safety, while the Asia Pacific region is witnessing rapid expansion due to rising healthcare expenditure, increasing disease burden, and improving healthcare infrastructure. Latin America and the Middle East & Africa are also experiencing steady growth, supported by government initiatives and international collaborations to enhance blood safety and diagnostic capabilities.

SARS-CoV-2 has caused symptomatic COVID-19 and widespread death across the globe. We sought to determine genetic variants contributing to COVID-19 susceptibility and hospitalization in a large biobank linked to a national United States health system. We identified 19,168 (3.7%) lab-confirmed COVID-19 cases among Million Veteran Program participants between March 1, 2020, and February 2, 2021, including 11,778 Whites, 4,893 Blacks, and 2,497 Hispanics. A multi-population genome-wide association study (GWAS) for COVID-19 outcomes identified four independent genetic variants (rs8176719, rs73062389, rs60870724, and rs73910904) contributing to COVID-19 positivity, including one novel locus found exclusively among Hispanics. We replicated eight of nine previously reported genetic associations at an alpha of 0.05 in at least one population-specific or the multi-population meta-analysis for one of the four MVP COVID-19 outcomes. We used rs8176719 and three additional variants to accurately infer ABO blood types. We found that A, AB, and B blood types were associated with testing positive for COVID-19 compared with O blood type with the highest risk for the A blood group. We did not observe any genome-wide significant associations for COVID-19 severity outcomes among those testing positive. Our study replicates prior GWAS findings associated with testing positive for COVID-19 among mostly White samples and extends findings at three loci to Black and Hispanic individuals. We also report a new locus among Hispanics requiring further investigation. These findings may aid in the identification of novel therapeutic agents to decrease the morbidity and mortality of COVID-19 across all major ancestral populations.

Blood Meal market has been steadily increasing over recent years, and forecasts suggest a substantial growth trajectory in the upcoming period.

Battlefield Blood-Substitute Market Outlook

According to our latest research, the Global Battlefield Blood-Substitute market size was valued at $1.12 billion in 2024 and is projected to reach $3.25 billion by 2033, expanding at a robust CAGR of 12.4% during 2024–2033. The primary driver fueling this growth is the urgent need for rapid, safe, and effective blood replacement solutions in combat and emergency scenarios, where traditional blood transfusion is often logistically challenging or impossible. The increasing frequency of armed conflicts, natural disasters, and large-scale emergencies globally is intensifying demand for advanced battlefield blood-substitute products that can be easily stored, transported, and administered without the constraints of blood type matching or refrigeration, thereby revolutionizing trauma care in critical environments.

Regional Outlook

North America currently dominates the battlefield blood-substitute market, accounting for the largest share at approximately 38% of the global market in 2024. This region’s leadership is underpinned by its mature healthcare infrastructure, significant defense spending, and ongoing investments in medical innovation. The United States, in particular, benefits from robust governmental support for military medical research and a well-established network of trauma centers, which accelerates the adoption of novel blood-substitute technologies. Additionally, favorable regulatory pathways and collaborations between defense agencies and biotech firms further contribute to North America’s commanding position. These factors, combined with a high incidence of trauma cases and a proactive approach to battlefield medicine, ensure that North America remains at the forefront of the battlefield blood-substitute industry’s evolution.

The Asia Pacific region is projected to be the fastest-growing market, with a remarkable CAGR of 15.8% during the forecast period. This accelerated growth is driven by increasing defense budgets across countries such as China, India, and South Korea, along with a heightened focus on emergency preparedness and military modernization. Rapid urbanization, frequent natural disasters, and regional conflicts have prompted governments to invest heavily in advanced trauma care solutions, including blood-substitute products. Furthermore, the rise of local biotech startups and partnerships with international players are fostering innovation and improving accessibility. The expansion of healthcare infrastructure and the growing recognition of the importance of rapid, field-deployable medical solutions are expected to further propel the Asia Pacific market’s growth trajectory.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of battlefield blood-substitute products is gradually increasing, albeit at a slower pace due to infrastructural and economic challenges. These regions face significant hurdles, including limited access to advanced medical technologies, inadequate supply chain networks, and a lack of standardized training for emergency responders. However, localized demand is rising in response to ongoing regional conflicts, terrorism, and disaster-prone environments. Policymakers are beginning to recognize the life-saving potential of blood substitutes, leading to targeted investments and pilot programs. While regulatory frameworks and reimbursement policies remain fragmented, international aid and collaborative efforts are helping to bridge some of these gaps, paving the way for future market expansion in these high-need areas.

Report Scope